ArticleiScience2023
The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC.
Rui Han et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ArticleiScience2023
Rui Han et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.